The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation.
The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation.
While the Bourgogne-Franche-Comté region is the birthplace of microtechnology, it is the combination of those technologies with cell therapies that enabled the RIGHT institute to bring out flagship products like CAR-T cells!
These innovations will be highlighted on the 20th and 21st of September, 2022, since Besançon will welcome the biggest global players specialised in the development of innovative therapies, their production and their regulatory supervision.
9:00-09:20 : WELCOME AND INTRODUCTION (KURSAAL CONF ROOM)
9:20-12:30 : CAR-T CELLS (I) (KURSAAL CONF ROOM)
Chairmen: Dr Christophe Ferrand and Dr Marina Deschamps, RIGHT Institute, Besançon, FR
09:20 : DECODING THE MODES OF ACTION OF CAR T CELLS USING INTRAVITAL IMAGING
Dr Philippe Bousso, Institut Pasteur and Inserm, Paris, FR
09:50 : ENDOWING UNIVERSAL CAR T-CELL WITH IMMUNE-EVASIVE PROPERTIES USING TALEN-GENE EDITING
Dr Julien Valton, Cellectis, Paris, FR
10:20 : GOLD SPONSOR PITCH (X2)
10:30 : BREAK
11:00 : CHINESE EXPERIENCE AND LANDSCAPE OF CART-CELLS IN CHINA
Pr Huang He, Bone Marrow Transplantation Center and Institute of Hematology , Zhejiang University, Hangzhou , PRC
11:30 : IS HOSPITAL EXEMPTION AN ALTERNATIVE OR A BRIDGE TO EUROPEAN MEDICINES AGENCY FOR DEVELOPING ACADEMIC CHIMERIC ANTIGEN RECEPTOR T-CELL IN EUROPE? SPANISH PUBLIC/ACADEMIC EXPERIENCE IN CART IN ACUTE LYMPHOID LEUKEMIA AND MULTIPLE MYELOMA
Dr Álvaro Urbano Ispizua, Hospital Clínic de Barcelona, SP
12:00 : DESCAR-T REGISTRY: LESSONS LEARNED FROM THE FRENCH REAL-LIFE DATABASE FOR CAR T CELLS IN HEMATOLOGIC MALIGNANCIES
Pr Roch Houot, UMR INSERM U1236, Rennes, FR
12:30 : GOLD SPONSOR PITCH (X2)
12:35-14:00 : LUNCH (KURSAAL BALLROOM )
13:00-16:30 : B2B MEETINGS
14:00-16:15 : VISIT OF BIOINNOVATION
16:00-16:30 : BREAK
16:30-19:30 : CELL AND CELL-DERIVED THERAPIES (KURSAAL CONF ROOM)
Chairmen: Dr Sylvain Perruche, RIGHT Institute, Besançon, FR & Dr Suman Mitra, INSERM, Lille, FR
16:30 : CELL THERAPY IN STROKE
Pr Olivier Detante, Grenoble Institute of Neuroscience, Grenoble, FR
17:00 : TRANSLATION IN CELL AND GENE THERAPY : STATUS, CHALLENGES AND OPPORTUNITIES
Dr Miguel Forte, ISCT, Charleroi, BE
17:30 : OPTIMIZING FUNCTIONS OF ADOPTIVELY TRANSFERRED TUMOR-SPECIFIC T CELLS
Dr Nathalie Labarriere , INCIT, UMR 1302, Nantes, FR
18:00 : GOLD SPONSOR PITCH
18:05 : COFFEE BREAK
18:30 : NEW CLASS OF CANCER VACCINE BASED ON AN OFF-THE-SHELF ANTIGEN PRESENTING CELL LINE
Eric Halioua, PDC*line Pharma, Liège, BE
19:00 : CLINICALLY TRANSLATABLE CYTOKINE FACTORIES FOR CANCER IMMUNOTHERAPY
Dr Omid Veiseh, Rice University, Houston, USA
20:00-23:30 : EVENING RECEPTION (KURSAAL BALLROOM)
9:00-11:00 : REGULATION, PRODUCTION AND CLINICAL TRANSFER OF INNOVATIVE THERAPIES (KURSAAL CONF ROOM)
Chairwoman: Dr Mathilde Girard, ADHARA, subsidiary of the URGO Group, Chenôve, and Dr Mathieu Guerriaud, CREDIMI, Dijon, FR
09:00 : INNOVATION SANTÉ 2030 PLAN, HOW FRANCE CAN FACILITATE THE DEVELOPMENT OF INNOVATIVE THERAPIES ? FOCUS ON THE BIOTHERAPY – BIOPRODUCTION INTEGRATORS NETWORK
Emmanuel DEQUIER, « Grand défi Biomedicaments », Secrétariat Général pour l’Investissement, Paris, FR
09:30 : ACCELERATING MEDICAL INNOVATION FROM RESEARCH TO PATIENTS
Andreas Wallnöfer, Jeito Capital, Paris, FR
10:00 : BREAK
10:30 : NEW CLINICAL TRIALS REGULATION: EUROPEAN COOPERATION FOR INNOVATION
Dr Claire Gérard, Agence nationale de sécurité du médicament et des produits de santé (ANSM), Lyon, FR
11:00 : UPCOMING INTERVENTION
11:30 : RNA-BASED DRUGS AND REGULATION: TOWARDS A NECESSARY EVOLUTION OF THE DEFINITIONS ISSUED FROM THE EUROPEAN UNION LEGISLATION
Dr Mathieu Guerriaud, CREDIMI, Dijon, in collaboration with Pr Evelyne Kohli, INSERM LNC-UMR1231, Dijon, FR
12:00-14:00 : LUNCH (KURSAAL BALLROOM )
12:30-14:00 B2B MEETINGS (KURSAAL BALLROOM)
14:00-17:00 RNA AS RAW MATERIELS & THERAPEUTICS (KURSAAL CONF ROOM)
Chairman : Dr Philippe DULIEU, RD Biotech, Besançon, FR ; and Pr Olivier ADOTEVI, RIGHT Institute, Besançon, FR
14:00 : MESSENGER RNA-BASED THERAPEUTICS: CURRENT STATUS, OPPORTUNITIES AND CHALLENGES
Pr Chantal Pichon, Center for Molecular Biophysics -UPR4301 CNRS, Orléans, FR
14:30 : INSIGHTS INTO THE PROCESS DEVELOPMENT AND MANUFACTURE OF MRNA VACCINES’
Phil Challis, eTheRNA, Niel, BE
15:00 : MICRORNA AS A TOOL FOR ENGINEERING NEXT GENERATION CAR T-CELLS
Dr Marco Alessandrini, Antion Biosciences, Geneva, CH
15:30 : COFFEE BREAK
16:00 : A LENTIVIRAL PLATFORM FOR EFFICIENT AND SAFE RNA DELIVERY
Pascale Bouillé, Flash Therapeutics, Toulouse, FR
16:30 : MODERNA’S MRNA PLATFORM AND APPLICATIONS TO VACCINES AGAINST INFECTIOUS DISEASES
Dr Carole Henry, Moderna, Cambridge, Massachusetts, USA
17:00 : CONCLUSION END OF CONGRESS
17:15 : BEER PARTY